Use of Probiotics to Prevent Cholangitis in Children With Biliary Atresia After the Kasai Portoenterostomy

• Register: ClinicalTrials.gov
• Last refreshed on: 19 February 2015
• Main ID: NCT00166868
• Date of registration: 12/09/2005
• Prospective Registration: No
• Primary sponsor: National Taiwan University Hospital
• Public title: Use of Probiotics to Prevent Cholangitis in Children With Biliary Atresia After the Kasai Portoenterostomy
• Scientific title: Use of Probiotics to Prevent Cholangitis in Children With Biliary Atresia
• Date of first enrolment: December 2003
• Target sample size: 30
• Recruitment status: Completed
• URL: http://clinicaltrials.gov/show/NCT00166868
• Study type: Interventional
• Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
• Phase: N/A

Countries of recruitment

Taiwan

Contacts

• Name: Mei-Hwei Chang, Professor
• Affiliation: National Taiwan University

Key inclusion & exclusion criteria

Inclusion Criteria:

- Biliary atresia patients aged 0 to 3 years, who had a Kasai operation

Exclusion Criteria:

- The patients who had received liver transplantation



Age minimum: 4 Months
Age maximum: 3 Years
Gender: Both

Health Condition(s) or Problem(s) studied

Biliary Atresia

Intervention(s)

Drug: Lactobacillus casei rhamnosus (Lcr35)

Drug: Neomycin

Primary Outcome(s)

episodes of cholangitis [Time Frame: 6 months after intervention]

Secondary Outcome(s)

gain of body weight [Time Frame: 6 months after intervention]

Secondary ID(s)

921201

Source(s) of Monetary Support

Please refer to primary and secondary sponsors